vs
Amneal Pharmaceuticals, Inc.（AMRX）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是UiPath, Inc.的1.8倍（$722.5M vs $411.1M），UiPath, Inc.净利率更高（48.4% vs 10.8%，领先37.6%），UiPath, Inc.同比增速更快（15.9% vs 3.9%），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（1.5% vs 0.7%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
AMRX vs PATH — 直观对比
营收规模更大
AMRX
是对方的1.8倍
$411.1M
营收增速更快
PATH
高出12.0%
3.9%
净利率更高
PATH
高出37.6%
10.8%
两年增速更快
AMRX
近两年复合增速
0.7%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $411.1M |
| 净利润 | $78.0M | $198.8M |
| 毛利率 | 44.3% | 83.3% |
| 营业利润率 | — | 3.2% |
| 净利率 | 10.8% | 48.4% |
| 营收同比 | 3.9% | 15.9% |
| 净利润同比 | 217.0% | 1966.2% |
| 每股收益（稀释后） | $0.19 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXPATH
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $411.1M | ||
| Q3 25 | $784.5M | $361.7M | ||
| Q2 25 | $724.5M | $356.6M | ||
| Q1 25 | $695.4M | $423.6M | ||
| Q4 24 | $730.5M | $354.7M | ||
| Q3 24 | $702.5M | $316.3M | ||
| Q2 24 | $701.8M | $335.1M |
净利润AMRXPATH
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $198.8M | ||
| Q3 25 | $2.4M | $1.6M | ||
| Q2 25 | $22.4M | $-22.6M | ||
| Q1 25 | $12.2M | $51.8M | ||
| Q4 24 | $-31.1M | $-10.7M | ||
| Q3 24 | $-156.0K | $-86.1M | ||
| Q2 24 | $6.0M | $-28.7M |
毛利率AMRXPATH
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 83.3% | ||
| Q3 25 | 34.9% | 82.2% | ||
| Q2 25 | 39.5% | 82.1% | ||
| Q1 25 | 36.8% | 84.8% | ||
| Q4 24 | 36.0% | 82.0% | ||
| Q3 24 | 38.4% | 80.0% | ||
| Q2 24 | 35.6% | 83.5% |
营业利润率AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 3.2% | ||
| Q3 25 | 9.0% | -5.6% | ||
| Q2 25 | 15.4% | -4.6% | ||
| Q1 25 | 14.4% | 7.9% | ||
| Q4 24 | 10.4% | -12.2% | ||
| Q3 24 | 12.6% | -32.7% | ||
| Q2 24 | 13.6% | -14.8% |
净利率AMRXPATH
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 48.4% | ||
| Q3 25 | 0.3% | 0.4% | ||
| Q2 25 | 3.1% | -6.3% | ||
| Q1 25 | 1.8% | 12.2% | ||
| Q4 24 | -4.3% | -3.0% | ||
| Q3 24 | -0.0% | -27.2% | ||
| Q2 24 | 0.9% | -8.6% |
每股收益（稀释后）AMRXPATH
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.37 | ||
| Q3 25 | $0.01 | $0.00 | ||
| Q2 25 | $0.07 | $-0.04 | ||
| Q1 25 | $0.04 | $0.09 | ||
| Q4 24 | $-0.10 | $-0.02 | ||
| Q3 24 | $0.00 | $-0.15 | ||
| Q2 24 | $0.02 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $1.9B |
| 总资产 | — | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $1.4B | ||
| Q3 25 | $201.2M | $1.4B | ||
| Q2 25 | $71.5M | $1.6B | ||
| Q1 25 | $59.2M | $1.6B | ||
| Q4 24 | $110.6M | $1.6B | ||
| Q3 24 | $74.0M | $1.7B | ||
| Q2 24 | $43.8M | $1.9B |
总债务AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $1.9B | ||
| Q3 25 | $-109.5M | $1.7B | ||
| Q2 25 | $-112.1M | $1.7B | ||
| Q1 25 | $-131.7M | $1.8B | ||
| Q4 24 | $-109.3M | $1.7B | ||
| Q3 24 | $-93.4M | $1.8B | ||
| Q2 24 | $-57.5M | $2.0B |
总资产AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $2.9B | ||
| Q3 25 | $3.6B | $2.6B | ||
| Q2 25 | $3.4B | $2.6B | ||
| Q1 25 | $3.4B | $2.9B | ||
| Q4 24 | $3.5B | $2.7B | ||
| Q3 24 | $3.5B | $2.7B | ||
| Q2 24 | $3.5B | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $28.3M |
| 自由现金流经营现金流 - 资本支出 | — | $25.1M |
| 自由现金流率自由现金流/营收 | — | 6.1% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | — | 0.14× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $28.3M | ||
| Q3 25 | $118.5M | $41.6M | ||
| Q2 25 | $83.8M | $119.0M | ||
| Q1 25 | $7.4M | $146.1M | ||
| Q4 24 | $118.1M | $28.1M | ||
| Q3 24 | $141.8M | $46.4M | ||
| Q2 24 | $39.7M | $100.0M |
自由现金流AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $25.1M | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | $106.2M | ||
| Q1 25 | $-5.8M | $138.7M | ||
| Q4 24 | $102.9M | $23.2M | ||
| Q3 24 | $124.8M | $45.0M | ||
| Q2 24 | $29.0M | $98.8M |
自由现金流率AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | 6.1% | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | 29.8% | ||
| Q1 25 | -0.8% | 32.7% | ||
| Q4 24 | 14.1% | 6.5% | ||
| Q3 24 | 17.8% | 14.2% | ||
| Q2 24 | 4.1% | 29.5% |
资本支出强度AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 0.8% | ||
| Q3 25 | 1.6% | 0.0% | ||
| Q2 25 | 3.2% | 3.6% | ||
| Q1 25 | 1.9% | 1.7% | ||
| Q4 24 | 2.1% | 1.4% | ||
| Q3 24 | 2.4% | 0.4% | ||
| Q2 24 | 1.5% | 0.4% |
现金转化率AMRXPATH
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 0.14× | ||
| Q3 25 | 50.00× | 26.25× | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
